Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Clasificación en acciones #29898
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Precio por acción
$1.10
Última sincronización: 2023-06-07
Capitalización bursátil
$19.12M
Cambio (1 día)
-0.90%
Cambio (1 año)
0.00%
País
US
Comercio Satsuma Pharmaceuticals, Inc. (STSA)

Categoría

Ratio P/B de Satsuma Pharmaceuticals, Inc. (STSA)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Satsuma Pharmaceuticals, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Satsuma Pharmaceuticals, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR